Non-steroidal anti-inflammatory drugs and their benefits and harms: The challenge of interpreting meta-analyses and observational data sets when balanced data are not analyzed and reported

Arthritis Research and Therapy

Volumn 17, Issue 1, 2015, Pages

  Simon, Lee S ^a  

^a SDG LLC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

NONSTEROID ANTIINFLAMMATORY AGENT;

CARDIOVASCULAR RISK; EDITORIAL; HUMAN; META ANALYSIS; OBSERVATIONAL STUDY; RISK ASSESSMENT; RISK FACTOR; META ANALYSIS (TOPIC);

ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; HUMANS; META-ANALYSIS AS TOPIC; OBSERVATIONAL STUDIES AS TOPIC;

EID: 84929466488     PISSN: 14786354     EISSN: 14786362     Source Type: Journal    
DOI: 10.1186/s13075-015-0650-1     Document Type: Editorial

References (10)

1. van Walsem A, Pandhiz S, Nixon RM, Guyot P, Karabis A, Moore AR. Relative benefit-risk comparing diclofenac to other traditional nonsteroidal anti-inflammatory drugs and cyclooxygenase-2 inhibitors in patients with osteoarthritis or rheumatoid arthritis: a network metaanalysis. Arthritis Res Ther. 2015;17:66.
2. Coxib and traditional NSAID Trialists' (CNT) Collaboration, Bhala N, Emberson J, Merhi A, Abramson S, Arber N, et al. Vascular and upper gastrointestinal effects of non-steroidal anti-inflammatory drugs: meta-analyses of individual participant data from randomised trials. Lancet. 2013;382:769-79.
3. US Food and Drug Administration. Joint meeting of the Arthritis Advisory Committee and the Drug Safety and Risk Management Advisory Committee. 10-11 February 2014. http://www.fda.gov/AdvisoryCommittees/Calendar/ucm380871.htm . Accessed 25 February 2015.
4. Simon LS, Lanza FL, Lipsky PE, Hubbard RC, Talwalker S, Schwartz BD, et al. Preliminary study of the safety and efficacy of SC-58635, a novel cyclooxygenase 2 inhibitor. Arthritis Rheum. 1998;41:1591-602.
5. Moore RA, Derry S, Simon LS, Emery P. Nonsteroidal anti-inflammatory drugs, gastroprotection, and benefit-risk. Pain Pract. 2014;14:378-95.
6. Sokka T, Pincus T. Poor physical function, pain and limited exercise: risk factors for premature mortality in the range of smoking or hypertension, identified on a simple patient self-report questionnaire for usual care. BMJ Open. 2011;1, e000070.
7. Nuesch E, Dieppe P, Reichenbach S, Williams S, Iff S, Juni P. All cause and disease specific mortality in patients with knee or hip osteoarthritis: population based cohort study. BMJ. 2011;342:d1165.
8. Goodson NJ, Brookhart AM, Symmons DP, Silman AJ, Solomon DH. Non-steroidal anti-inflammatory drug use does not appear to be associated with increased cardiovascular mortality in patients with inflammatory polyarthritis: results from a primary care based inception cohort of patients. Ann Rheum Dis. 2009;68:367-72.
9. Solomon DH, Rassen JA, Glynn RJ, Lee J, Levin R, Schneeweiss S. The comparative safety of analgesics in older adults with arthritis. Arch Intern Med. 2010;170:1968-76.
10. Antman EM, Bennett JS, Daugherty A, Furberg C, Roberts H, Taubert KA, et al. Use of nonsteroidal antiinflammatory drugs: an update for clinicians: a scientific statement from the American Heart Association. Circulation. 2007;115:1634-42.